Bioinformatics analyses combined microarray identify the deregulated microRNAs in oral cancer

Oncology Letters

Volumn 8, Issue 1, 2014, Pages 218-222

  Cui, Jing ^a,b   Li, Dalu ^a   Zhang, Wenmei ^a   Shen, Liang ^c   Xu, Xin ^b  

^a JINAN STOMATOLOGICAL HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

hsa miR 15a; microRNA; Oral cancer

Indexed keywords

APC PROTEIN; ATM PROTEIN; BMI1 PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CD28 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLIN DEPENDENT KINASE 6; CYTOCHROME P450 1B1; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; HERMES ANTIGEN; HIGH MOBILITY GROUP A2 PROTEIN; K RAS PROTEIN; MICRORNA; MICRORNA 15A; MICROTUBULE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 5; P21 ACTIVATED KINASE 1; PROTEIN BCL 2; PROTEIN KINASE PIM 1; RAC1 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR SOX2; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CELL DEATH; CELL MIGRATION; CELL MOTILITY; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DATA BASE; GENE EXPRESSION; GENE IDENTIFICATION; GENE ONTOLOGY; GENE TARGETING; HISTOLOGY; HUMAN; MICROARRAY ANALYSIS; MOUTH CANCER; NUCLEOTIDE SEQUENCE; PREDICTION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84901198145     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2070     Document Type: Article

References (27)

1. Zygogianni AG, Kyrgias G, Karakitsos P, et al: Oral squamous cell cancer: early detection and the role of alcohol and smoking. Head Neck Oncol 3: 2, 2011.
2. Zini A, Czerninski R and Sgan-Cohen HD: Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J Oral Pathol Med 39: 299-305, 2010.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
4. Mirnezami AH, Pickard K, Zhang L, Primrose JN and Packham G: MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol 35: 339-347, 2009.
5. Ruan K, Fang X and Ouyang G: MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285: 116-126, 2009.
6. Cicatiello L, Mutarelli M, Grober OM, Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol 176: 2113-2130, 2010.
7. Siow M, Karen Ng L, Vincent Chong V, Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis: Apr 17, 2013 (Epub ahead of print) doi: 10.1111/odi.12118.
8. Jung HM, Phillips BL, Patel RS, et al: Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECK) in oral cancer. J Biol Chem 287: 29261-29272, 2012.
9. Franceschini A, Szklarczyk D, Frankild S, STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41: D808-D815, 2013.
10. Cimmino A, Calin GA, Fabbri M, miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949, 2005.
11. Calin GA, Cimmino A, Fabbri M, MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 105: 5166-5171, 2008.
12. Urbich C, Kuehbacher A and Dimmeler S: Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 79: 581-588, 2008.
13. Bonci D, Coppola V, Musumeci M, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277, 2008.
14. Bandi N, Zbinden S, Gugger M, miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69: 5553-5559, 2009.
15. Xin C, Buhe B, Hongting L, MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression. FEBS J 280: 855-866, 2013.
16. Ricieri Brito JA, Gomes CC, Santos Pimenta FJ, et al: Reduced expression of mir15a in the blood of patients with oral squamous cell carcinoma is associated with tumor staging. Exp Ther Med 1: 217-221, 2010.
17. Okada-Ban M, Thiery JP and Jouanneau J: Fibroblast growth factor-2. Int J Biochem Cell Biol 32: 263-267, 2000.
18. Dow JK and deVere White RW: Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 55: 800-806, 2000.
19. Chalkiadaki G, Nikitovic D, Berdiaki A, et al: Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism. Int J Biochem Cell Biol 41: 1323-1331, 2009.
20. Giri D, Ropiquet F and Ittmann M: Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071, 1999.
21. Cross MJ and Claesson-Welsh L: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22: 201-207, 2001.
22. Lau MT, So WK and Leung PC: Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One 8: e59083, 2013.
23. Kelleher FC, O'Sullivan H, Smyth E, McDermott R and Viterbo A: Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis 34: 2198-2205, 2013.
24. Liang G, Chen G, Wei X, Zhao Y and Li X: Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev 24: 467-475, 2013.
25. Weiss J, Sos ML, Seidel D, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2: 62ra93, 2010.
26. Dutt A, Salvesen HB, Chen TH, et al: Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105: 8713-8717, 2008.
27. Kunii K, Davis L, Gorenstein J, et al: FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 68: 2340-2348, 2008.